pembrolizumab,Talabostat
merck,BioXcel Therapeutics
['pembro', 'thank you', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
thank you to of for stopping in to discuss key findings from the phase 2a trial of talabostat plus pembrolizumab in mcrpc. to learn more about dr. aggarwal's presentation, and other trials read out at #gu23, visit us at 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.